Daily Stock Analysis, EPZM, Epizyme Inc, priceseries

Epizyme Inc. Daily Stock Analysis
Stock Information
Open
15.99
Close
16.66
High
16.74
Low
15.77
Previous Close
16.04
Daily Price Gain
0.62
YTD High
16.74
YTD High Date
Nov 20, 2019
YTD Low
5.81
YTD Low Date
Jan 2, 2019
YTD Price Change
9.99
YTD Gain
149.78%
52 Week High
16.74
52 Week High Date
Nov 20, 2019
52 Week Low
5.14
52 Week Low Date
Dec 24, 2018
52 Week Price Change
9.66
52 Week Gain
138.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 2. 2017
11.25
Feb 22. 2017
12.14
13 Trading Days
7.90%
Link
LONG
Jun 14. 2017
12.35
Jul 6. 2017
14.91
15 Trading Days
20.75%
Link
LONG
Aug 14. 2017
13.25
Sep 12. 2017
17.17
20 Trading Days
29.59%
Link
LONG
Jan 19. 2018
15.25
Jan 31. 2018
16.35
8 Trading Days
7.19%
Link
LONG
May 8. 2018
14.20
May 31. 2018
17.46
16 Trading Days
22.96%
Link
LONG
Dec 28. 2018
6.04
Jan 3. 2019
6.37
3 Trading Days
5.46%
Link
LONG
Jan 4. 2019
7.94
Jan 22. 2019
8.98
11 Trading Days
13.09%
Link
LONG
Jan 29. 2019
9.55
Feb 21. 2019
11.81
16 Trading Days
23.62%
Link
LONG
Mar 28. 2019
12.15
Apr 12. 2019
13.09
11 Trading Days
7.76%
Link
Company Information
Stock Symbol
EPZM
Exchange
NasdaqGS
Company URL
http://www.epizyme.com
Company Phone
617-229-5872
CEO
Robert B. Bazemore
Headquarters
Massachusetts
Business Address
400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001571498
About

Epizyme, Inc. operates as a clinical stage biopharmaceutical company. The company discovers, develops and plans to commercialize therapeutics for patients with genetically defined cancers. It engages in the creation of small molecule inhibitors of class of enzymes known as histone methyltransferases. The company products include Tazemetostat, which is used for the treatment of multiple types of hematological malignancies and genetically defined solid tumors; and Pinometostat, which is used for treatment of patients with MLL-r, a genetically defined acute leukemia. Epizyme was founded by H. Robert Horvitz and Yi Zhang on November 1, 2007 and is headquartered in Cambridge, MA.

Description

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.